Meridian Bioscience (VIVO) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $2.21 -6.36%
Financial Fact:
Selling and marketing: 8.13M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Selling and marketing: 8.13M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.19, $0.03 better than the analyst estimate of $0.16. Revenue for the quarter came in at $50.2 million versus the consensus estimate of $51.74 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple (AAPL) Tops Q4 EPS by 11c, Beats on Revenue, Beats on iPhone sales, Misses China
- Inspire Medical Systems (INSP) Tops Q3 EPS by 5c, Beats on Revenue; Offers FY26 Guidance
- HealthStream (HSTM) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
